BC
PCVX icon

Bridgefront Capital’s Vaxcyte PCVX Stock Holding History

Bridgefront Capital’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-24,325
Closed -$876K – 717
2025
Q3 		$876K Buy
24,325
+13,617
+127% +$451K 0.26% 116
2025
Q2 		$348K Buy
+10,708
New +$351K 0.09% 386
2025
Q1 		– Sell
-4,244
Closed -$347K – 795
2024
Q4 		$347K Buy
4,244
+172
+4% +$17.1K 0.12% 315
2024
Q3 		$465K Buy
+4,072
New +$367K 0.18% 196
2024
Q2 		– Sell
-6,594
Closed -$450K – 622
2024
Q1 		$450K Buy
6,594
+3,385
+105% +$234K 0.34% 90
2023
Q4 		$202K Buy
+3,209
New +$167K 0.15% 297

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Bridgefront Capital's PCVX Position: Q4 2025 in Review

Bridgefront Capital sold out of Vaxcyte (PCVX) in Q4 2025, closing a stake of 24,325 shares — an estimated $876K sold.

Bridgefront Capital first reported a position in PCVX in Q4 2023 and held it in 6 quarters. The position peaked at $876K in Q3 2025. 295 funds tracked by Wall St. Rank hold PCVX as of Q4 2025.

  • Bridgefront Capital reported no remaining Vaxcyte position as of Q4 2025 after selling out during the quarter.
  • Bridgefront Capital sold 24,325 Vaxcyte shares in Q4 2025, an estimated $876K.
  • Bridgefront Capital first reported a position in Vaxcyte in Q4 2023 and held it in 6 quarters.
  • Bridgefront Capital's Vaxcyte position peaked at $876K in Q3 2025.
  • 295 funds tracked by Wall St. Rank held Vaxcyte as of Q4 2025.

Based on Bridgefront Capital's 13F filing for Q4 2025, filed 13 Feb 2026.